Day One

Wednesday July 14, 2021

Day Two

Thursday July 15, 2021

09:00 - 17:30 EST | 6.00 - 14.30 PST

* Please note that the following agenda timings are Eastern Standard Time.  

For full agenda session details and Pacific Standard Times, please download the full event guide here

8:30 am Join Our Morning Coffee Chatroom to Get Started!

8:45 am Chair’s Opening Remarks

Discovering Best-In-Class Models for Cell & Combination Therapies

9:00 am Translational Preclinical Platforms for CAR-T Cell Therapy

  • Rekha Pal Director & Scientific Engagement, Crown Bioscience

9:30 am Evaluate Immune Restoring CAR-T Cell Therapy on Clear Cell Renal Cell Carcinoma (ccRCC) Patient Derived Rrganotypic Spheroids (PDOTs) & Humanized Mouse Model

  • Yufei Wang Research Fellow Dana-Faber, Cancer Institute

9:50 am BRGSF-HIS Mouse: A Robust & Translatable New Model to Assess the Human Immune Response to Immunotherapies

  • Kader Thiam Senior Vice President Discovery - Preclinical Models & Services, GenOway

10:20 am Live Q&A – Ask Our Speakers Your Burning Questions

  • Rekha Pal Director & Scientific Engagement, Crown Bioscience
  • Yufei Wang Research Fellow Dana-Faber, Cancer Institute
  • Kader Thiam Senior Vice President Discovery - Preclinical Models & Services, GenOway

10:40 am Speed Networking

10:55 am Morning Networking Break & 1-2-1 Meetings

Preclinical Track

Emerging Models & Trends

11:10 am Parallel CAR Targetting of Solid Tumors in Xenograft Models

  • John Maher Senior Lecturer - Clinical Immunology, King’s College London

11:30 am Enabling Patient-Centric Cancer R&D with Primary Tissues & Pharmacoscopy®

11:45 am Innate Immune Checkpoints in Tumor Immunotherapy

  • Martina Molgora Postdoctoral Researcher Washington, University School of Medicine

12:05 pm Live Q&A

  • John Maher Senior Lecturer - Clinical Immunology, King’s College London
  • Martina Molgora Postdoctoral Researcher Washington, University School of Medicine
  • Nikolaus Krall Chief Executive Officer & Co-founder, Allcyte

Translational Track

Single-Cell Analytics & Cancer Drug Resistance

11:10 am Using Single-Cell Omics to Better Understand Tumor Complexity

  • Natasha Darras Director, Cell Therapy Translational Medicine, Takeda Oncology

11:30 am Overcoming Cancer Drug Resistance

11:50 am The Role of Translational Medicine in Supporting Product Developmen: An Axi-Cel Case Study

  • Simone Filosto Principal Scientist, Translational Research & Clinical Pharmacology, Kite Pharma

12:10 pm Live Q&A

  • Natasha Darras Director, Cell Therapy Translational Medicine, Takeda Oncology
  • Shiva Kazerounian Associate Director of in Vivo Pharmacology, Berg Health
  • Simone Filosto Principal Scientist, Translational Research & Clinical Pharmacology, Kite Pharma

12:30 pm Scientific Poster Session & Lunch Break

Model Innovation for Preclinical Evaluation of Novel Therapeutics

1:30 pm Harnessing the Power of Next Gen In Vitro Models for Oncology Discovery & Development

  • Leo Price Senior Vice President, In Vitro, Crown Bioscience

1:45 pm GEM-Derived Allograft Models of Pancreatic Cancer: Valuable Tool for Preclinical Evaluation of Cominatorial Immunotherapies

2:05 pm Live Q&A

2:30 pm Roundtable Discussion: Predictability of Cell Therapies

Deep Dive Into Efficacy & Safety

1:30 pm Assessing CAR-T Efficacy in Xenograft Models: Examples of Structure Activity Relationship

1:50 pm The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

  • Dongfang Liu Associate Professor & Director - Immunoassay Development Program, Rutgers New Jersey Medical School

2:10 pm Relevant Humanized Models for the Evaluation of Efficacy and Safety of Targeted Innate Immunity Agonists for Immuno-Oncology

2:30 pm Live Q&A

  • Boris Engels Associate Director, Novartis
  • Anton Neschadim Chief Executive Officer & Director, ImmunoBiochem Corp
  • Dongfang Liu Associate Professor & Director - Immunoassay Development Program, Rutgers New Jersey Medical School

2:55 pm Networking Break & 1-2-1 Meetings

Advancements in Combination Cell Therapies & Emerging Candidates

3:20 pm New Humanized Mouse Models to Support NK Cell Research

  • Grace Berryhill Senior Technical Information Scientist, The Jackson Laboratory

3:50 pm Comparison of New Syngeneic Mouse Models & Human Organoids with Single Cell Sequencing

4:10 pm Generation of a CD19-CAR T Cell Therapy as a Tool for Preclinical Combination Strategies

  • Sheri Barnes Associate Director - Scientific Development, Labcorp Drug Development

4:25 pm Live Q&A – Ask Our Speakers Your Burning Questions

  • Joshua Breunig Associate Professor, Cedars-Sinai Medical Centre
  • Grace Berryhill Senior Technical Information Scientist, The Jackson Laboratory
  • Sheri Barnes Associate Director - Scientific Development, Labcorp Drug Development

4:40 pm Panel Discussion: Organoids vs Humanized Mice – Modelling of the Tumor Landscape

  • Joshua Breunig Associate Professor, Cedars-Sinai Medical Centre
  • Brian Soper Senior Technical Information Scientist, The Jackson Laboratory
  • Yufei Wang Research Fellow Dana-Faber, Cancer Institute
  • Leo Price Senior Vice President, In Vitro, Crown Bioscience

5:25 pm Chair’s Closing Remarks & End of Conference Day One

View Conference Day 2